NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
54868-0173-00 | 54868-0173 | methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | March 26, 2003 | In Use | |
54868-4143-00 | 54868-4143 | Capecitabine | Xeloda | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 20, 2005 | In Use | |
54868-5667-00 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-01 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-02 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-03 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
55289-0924-30 | 55289-0924 | METHOTREXATE | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 23, 2009 | Aug. 3, 2018 | No Longer Used |
55292-0911-51 | 55292-0911 | Mechlorethamine hydrochloride | Mustargen | 10.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intracavitary, Intravenous | March 15, 1949 | March 31, 2019 | No Longer Used |
00093-8229-28 | 00093-8229 | Sunitinib Malate | Sunitinib Malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use | |
00093-8231-28 | 00093-8231 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use | |
00093-8224-28 | 00093-8224 | Sunitinib Malate | Sunitinib Malate | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use | |
00093-8199-28 | 00093-8199 | Sunitinib Malate | Sunitinib Malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use | |
00093-7662-56 | 00093-7662 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Dec. 8, 2021 | In Use | |
75834-0132-05 | 75834-0132 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0132-14 | 75834-0132 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0142-05 | 75834-0142 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0142-14 | 75834-0142 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0143-05 | 75834-0143 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0143-14 | 75834-0143 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0144-05 | 75834-0144 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0144-14 | 75834-0144 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0145-05 | 75834-0145 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
75834-0145-14 | 75834-0145 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 7, 2021 | In Use | |
42291-0321-01 | 42291-0321 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | July 23, 2013 | In Use | |
42291-0505-01 | 42291-0505 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 5, 2020 | In Use |
Found 10,000 results in 5 milliseconds — Export these results